6533b85bfe1ef96bd12bb511
RESEARCH PRODUCT
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial
Jorge García-gonzálezAlejandro Rodriguez-festaBartomeu MassutiM. GuiradoSilvia Calabuig-fariñasAna BlascoA. InsaSergio Vazquez EstévezJ. M. JuradoMiguel Angel Molina-vilaManuel CoboBerta HernandezMargarita MajemOscar Juan VidalPilar DizAna RoyuelaAtocha RomeroBeatriz García-peláezJavier Perez AltozanoGretel BenítezAna López MartínSantiago ViteriAna CollazoEloisa Jantus-lewintreMariano ProvencioCarlos Garcia GironPatricia CruzAna Laura OrtegaJoaquim Bosch-barreraR. Bernabésubject
0301 basic medicineOncologyMaleCancer Researchcell lung cancerIntraclass correlationBiopsyDNA Mutational Analysisnon-small cell lung cancer (NSCLC)Tyrosine kinase inhibitorTyrosine-kinase inhibitorCohort Studies*circulating free DNAT790M0302 clinical medicinetyrosine kinase inhibitorGene FrequencyOsimertinibProspective cohort studyCàncernon‐small‐cell lung cancerCirculating free DNARC254-282Research ArticlesSequence DeletionAged 80 and overNeoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-Throughput Nucleotide Sequencingnon‐General MedicineDNA NeoplasmExonsMiddle AgedErbB ReceptorsEpidermal growth factor receptor (EGFR) NGS Non-small cell lung cancer (NSCLC) PCR Tyrosine Kinase Inhibitor (TKI) circulating free DNA (cfDNA) osimertinibOncology030220 oncology & carcinogenesisosimertinibNGSMolecular Medicinesmall‐FemaleResearch Article*NGSAdultmedicine.medical_specialtymedicine.drug_classSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsInternal medicineGeneticsmedicineHumansAged*non-small-cell lung cancerbusiness.industryEpidermal growth factor receptorNon invasive*epidermal growth factor receptormedicine.disease*tyrosine kinase inhibitorrespiratory tract diseases030104 developmental biologyEgfr mutationPulmonsMutationcirculating free DNAbusinessepidermal growth factor receptorNon-small-cell lung cancer*osimertinibOsimertinibdescription
Plasma samples from 72 EGFR‐mutant advanced NSCLC patients, collected upon progression to first‐line TKI, were analyzed by seven methodologies (two NGS‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods). Our study demonstrates a good to excellent agreement between methodologies and supports the use of liquid biopsies for therapy decision‐making.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-11-13 |